SPI-1005 for the Treatment of Patients With Meniere's Disease
Status:
Completed
Trial end date:
2019-04-30
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, efficacy, and Pharmacokinetics (PK) of two dose levels
of SPI-1005 administered for 28 days compared to placebo in patients with Meniere's disease.